المؤلفون: Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Pencheva N; Genmab, Utrecht, the Netherlands., Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Altimari DD; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Castro PG; Genmab, Utrecht, the Netherlands., de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gresnigt-Van den Heuvel E; Genmab, Utrecht, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Song JY; Division of Animal Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Visser N; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Apriamashvili G; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Janmaat ML; Genmab, Utrecht, the Netherlands., Plantinga TS; Genmab, Utrecht, the Netherlands., Franken P; Genmab, Utrecht, the Netherlands., Houtkamp M; Genmab, Utrecht, the Netherlands., Lingnau A; Genmab, Utrecht, the Netherlands., Jure-Kunkel M; Genmab, Princeton, New Jersey., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. d.peeper@nki.nl.

المصدر: Cancer research [Cancer Res] 2021 Apr 01; Vol. 81 (7), pp. 1775-1787. Date of Electronic Publication: 2021 Feb 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Immune Checkpoint Inhibitors/*therapeutic use , Immunoconjugates/*therapeutic use , Lung Neoplasms/*therapy , Melanoma/*therapy , Proto-Oncogene Proteins/*immunology , Receptor Protein-Tyrosine Kinases/*immunology, Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Line, Tumor ; Combined Modality Therapy ; Drug Resistance, Neoplasm/immunology ; Drug Synergism ; HEK293 Cells ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immunoconjugates/administration & dosage ; Immunotherapy ; Lung Neoplasms/pathology ; Male ; Melanoma/pathology ; Mice ; Mice, Nude ; Mice, Transgenic ; Molecular Targeted Therapy/methods ; Proto-Oncogene Proteins/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Xenograft Model Antitumor Assays ; Axl Receptor Tyrosine Kinase

المؤلفون: Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Koopman LA; Genmab, Utrecht, the Netherlands., Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Shahrabi A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Heuvel EG; Genmab, Utrecht, the Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kemper K; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kuilman T; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Song JY; Division of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Pencheva N; Genmab, Utrecht, the Netherlands., Mortensen JT; Genmab, Utrecht, the Netherlands., Foppen MG; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Rozeman EA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Janmaat ML; Genmab, Utrecht, the Netherlands., Satijn D; Genmab, Utrecht, the Netherlands., Breij ECW; Genmab, Utrecht, the Netherlands., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Parren PWHI; Genmab, Utrecht, the Netherlands.; Department of Immunohematology & Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.

المصدر: Nature medicine [Nat Med] 2018 Feb; Vol. 24 (2), pp. 203-212. Date of Electronic Publication: 2018 Jan 15.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: Immunoconjugates/*pharmacology , Melanoma/*drug therapy , Proto-Oncogene Proteins/*immunology , Proto-Oncogene Proteins B-raf/*genetics , Receptor Protein-Tyrosine Kinases/*immunology, Animals ; Cell Line, Tumor ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/immunology ; Genetic Heterogeneity/drug effects ; Humans ; Immunoconjugates/immunology ; Melanoma/genetics ; Melanoma/immunology ; Melanoma/pathology ; Mice ; Oligopeptides/chemistry ; Oligopeptides/immunology ; Oligopeptides/pharmacology ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/immunology ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins/chemistry ; Proto-Oncogene Proteins/pharmacology ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/immunology ; Receptor Protein-Tyrosine Kinases/chemistry ; Receptor Protein-Tyrosine Kinases/pharmacology ; Xenograft Model Antitumor Assays ; Axl Receptor Tyrosine Kinase